Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 8, 2003, Pages 805-813

  Pantoflickova, D ^a   Corthesy Theulaz I ^b   Dorta, G ^a   Stolte, M ^c   Isler, P ^a   Rochat, F ^b   Enslen, M ^b   Blum, A L ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c Institut fur Pathologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIETARY INTAKE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FERMENTATION; FERMENTED MILK; GASTRITIS; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE FLORA; LACTOBACILLUS JOHNSONII; MALE; MILK; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCUS;

ADOLESCENT; ADULT; CULTURED MILK PRODUCTS; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; FLATULENCE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS; MALE; MIDDLE AGED; PYLORIC ANTRUM;

EID: 0142249444     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01675.x     Document Type: Article

References (37)

1. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000; 54: 615-40.
2. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between clinical presentation. Helicobacter pylori density, interleukin Iβ and 8 production, and cagA status. Gut 1999; 45: 804-11.
3. Tokunaga Y, Shirahase H, Hoppou T, Kitaoka A, Tokuka A, Ohsumi K. Density of Helicobacter pylori infection evaluated semiquantitatively in gastric cancer. J Clin Gastroenterol 2000; 31: 217-21.
4. Richter JE. H pylori: the bug is not all bad. Gut 2001; 49: 319-20.
5. Blaser MJ, Kirschner D. Dynamics of Helicobacter pylori colonization in relation to the host response. Proc Natl Acad Sci U S A 1999; 96: 8359-64.
6. Michetti P, Dorta G, Wiesel PH, et al Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60: 203-9.
7. 1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 13: 25-9.
8. Logan RP. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998; 43(Suppl. 1): S47-S50.
9. Price AB, Misiewicz JJ. Sydney classification for gastritis. Lancet 1991; 337: 174.
10. Stolte M, Batz CH, Bayerdorffer E, Eidt S. Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach. Z Gastroenterol 1995; 33: 198-201.
11. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116: 804-12.
12. Suter V, Citron D, Finegold S. In: Wadsworth Anaerobic Bacteriology Manual, 3rd edn. Appendix: Normal flora studies. St Louis-Toronto-London: The C.V. Mosby Company; 1980: 83-115.
13. Lowbury EJ, Lilly HA. A selective plate medium. J Pathol Bacteriol 1955; 70: 105-9.
14. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001; 47: 709-10.
15. Cats A, Kuipers EJ, Bosschaert MARL, Pot RG, Vandenbroucke-Grauls CM, Kusters JG. Effect of frequent consumption of Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003; 17: 429-35.
16. Park MJ, Kim JS, Jung HC, Song IS. The suppressive effect of a fermented milk containing Lactobacilli on Helicobacter pylori in human gastric mucosa. Gastroenterology 2001; G2998.
17. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14: 1625-9.
18. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillus-and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-75.
19. Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 2000; 14(6): 823-8.
20. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003; 94(3): 449-55.
21. Chauviere G, Coconnier MH, Kerneis S, Fourniat J, Servin AL. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Generalmicrobiol 1992; 138(8): 1689-96.
22. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276: G941-G950.
23. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 2000; 118: 1072-9.
24. Bernet-Camard MF, Lievin V, Brassart D, Neeser JR, Servin AL, Hudault S. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance (s) active in vitro and in vivo. Appl Environ Microbiol 1997; 63: 2747-53.
25. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998; 64: 4573-80.
26. Avonts L, De-Vuyst L. Antimicrobial potential of probiotic lactic acid bacteria. Mededelingen-Faculteit-Landbouwkundige-En-Toegepaste-Biologische- Wetenschappen-Universiteit-Gent 2001; 66: 543-5(Abstract).
27. Gill HS, Rutherfurd KJ, Prasad J, Gopal PK. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 2000; 83: 167-76.
28. Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. Am J Gastroenterol 2000; 95: S22-S25.
29. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001; 20: 149-56.
30. Vitini E, Alvarez S, Medina M, Medici M, de Budeguer MV, Perdigon G. Gut mucosal immunostimulation by lactic acid bacteria. Biocell 2000; 24: 223-32.
31. Murosaki S, Muroyama K, Yamamoto Y, Yoshikai Y. Antitumor effect of heat-killed Lactobacillus plantarum L-137 through restoration of impaired interleukin-12 production in tumor-bearing mice. Cancer Immunol Immunother 2000; 49: 157-64.
32. von Der Weid, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4 (+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Laboratory Immunol 2001; 8: 695-701.
33. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987; 37(Suppl. 2): 16-30.
34. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16(4): 292-4.
35. Alvarez W. Sixty years of vagotomy: a review of some 200 articles. Gastroenterology 1948; 10: 413-41.
36. Deering TB, Carlson GL, Malagelada JR, Duenes JA, McCall JT. Fate of oral neutralizing antacid and its effect on postprandial gastric secretion and emptying. Gastroenterology 1979; 77: 986-90.
37. Sonnenberg A. Threshold analysis of Helicobacter pylori therapy. Pharmacoeconomics 1998; 14: 423-32.